You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
歌禮制藥-B(01672.HK):ASC47與GLP-1R/GIPR雙受體激動劑多肽ASC31聯用在肥胖動物模型中顯示出優於ASC47與替爾泊肽聯用的減重效果

格隆匯8月18日丨歌禮制藥-B(01672.HK)發佈公告,同類首創的治療肥胖症的減重不減肌候選藥物ASC47與GLP-1受體(GLP-1R)/GIP受體(GIPR)雙靶點激動劑多肽ASC31聯用顯示出令人鼓舞的臨牀前療效結果。

ASC31是一款由歌禮自主研發的新型GLP-1R和GIPR雙靶點激動劑多肽,在非人靈長類動物中顯示出良好的藥代動力學特徵,同時顯示出積極的體外活性並在DIO小鼠中顯示出積極的體內療效。ASC31體現了歌禮應用超長效藥物開發平臺(Ultra-Long-Acting Platform,ULAP)自主研發新型皮下注射多肽和口服多肽的部分成果。ASC47是一款由歌禮自主研發的、脂肪靶向、每月一次皮下注射的甲狀腺激素受體β(THRβ)選擇性小分子激動劑。ASC47具有獨特的差異化特性,能夠靶向脂肪,從而在脂肪組織中產生劑量依賴性的高藥物濃度。

“我們的新型GLP-1R/GIPR雙受體激動劑多肽ASC31聯合THRβ激動劑ASC47在該動物模型中表現出優異的減重效果,這款新療法相較於已上市的減肥藥物及其他在研候選藥物展現出了顯著的差異化潛力,”歌禮創始人、董事會主席兼首席執行官吳勁梓博士表示,“歌禮正在構建一系列強健的、同時涵蓋小分子和多肽的肥胖症潛在療法的管線,我們期待在未來分享更多的進展。”

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account